Antipsychotics at doses >75 mg/day are associated with an increased risk for tardive dyskinesia (TD), according to a study ...

Researchers from the National Healthcare Group (NHG)'s Institute of Mental Health (IMH) and Agency for Science, Technology ...

There are as yet no effective drugs for negative symptoms like social withdrawal and lack of motivation. Read more at ...

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...

Brexpiprazole is used as an adjunctive therapy to antidepressants for the treatment of major depressive disorder in adults, ...

Treatment-resistant schizophrenia (TRS) is generally understood as a failure to respond to at least two trials of ...

Research suggests a link between schizophrenia and changes in the immune system, highlighting potential new pathways for ...

The FDA has approved Cobenfy, a new drug to treat people with schizophrenia that comes with fewer side effects.

LB Pharmaceuticals announced promising Phase II results for LB-102 in schizophrenia, demonstrating symptom improvement.

Abbvie said on Friday it would record a charge of about $3.5 billion related to its experimental schizophrenia drug, ...